Evidence map›Paper›PMID 38306687›Full record

Trial reportEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2024

Sequential hybrid ablation vs. surgical CryoMaze alone for treatment of atrial fibrillation: results of multicentre randomized controlled trial.

Alan Bulava, Dan Wichterle, Aleš Mokráček, Pavel Osmančík, Petr Budera, Petr Kačer, Linda Vetešková, Petr Němec, Tomáš Skála, Petr Šantavý and 7 more

Open access · hybridAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 1 country.

Alan BulavaFaculty of Health and Social Sciences, University of South Bohemia in České Budějovice and Cardiac Centre, České Budějovice Hospital, B. Němcové 54, 370 01 České Budějovice, Czechia.ORCID 0000-0002-1742-207X
Dan WichterleCardiology Department, Institute for Clinical and Experimental Medicine, Prague, Czechia.ORCID 0000-0002-0448-5143
Aleš MokráčekFaculty of Health and Social Sciences, University of South Bohemia in České Budějovice and Cardiac Centre, České Budějovice Hospital, B. Němcové 54, 370 01 České Budějovice, Czechia.
Pavel OsmančíkThird Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czechia.ORCID 0000-0003-0482-4448
Petr BuderaCardiology Department, Institute for Clinical and Experimental Medicine, Prague, Czechia.ORCID 0000-0001-5547-8704
Petr KačerThird Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czechia.ORCID 0000-0002-1662-5828
Linda VeteškováCentre of Cardiovascular Surgery and Transplantation, Brno, Czechia.
Petr NěmecCentre of Cardiovascular Surgery and Transplantation, Brno, Czechia.ORCID 0000-0002-4542-913X
Tomáš SkálaFaculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czechia.ORCID 0000-0002-4943-5588
Petr ŠantavýFaculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czechia.ORCID 0000-0002-6897-5344
Jan ChovančíkCardilogy Department, Hospital Agel Třinec-Podlesí, Třinec, Czechia.
Piotr BrannyCardilogy Department, Hospital Agel Třinec-Podlesí, Třinec, Czechia.ORCID 0009-0003-9471-6850
Vitalii RizovCardilogy Department, Masaryk Hospital, Ústí nad Labem, Czechia.ORCID 0009-0004-6603-4315
Miroslav KolesárCardilogy Department, Masaryk Hospital, Ústí nad Labem, Czechia.ORCID 0009-0008-6247-9850
Iva ŠafaříkováFaculty of Health and Social Sciences, University of South Bohemia in České Budějovice and Cardiac Centre, České Budějovice Hospital, B. Němcové 54, 370 01 České Budějovice, Czechia.ORCID 0000-0001-6776-3561
Marian RybářFaculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czechia.
SURHYB Trial Investigators
University of South Bohemia in České Budějovice · CZCharles University · CZUniversity Hospital Olomouc · CZCentrum kardiovaskulární a transplantační chirurgie · CZInstitute of Clinical and Experimental Medicine · CZKrajská Zdravotní · CZNemocnice Podlesí · CZCzech Technical University in Prague · CZ

Funding

Ministry of Health of the Czech Republic NV19-02-00046
6 · The paper itself

Abstract

aimsData on the hybrid atrial fibrillation (AF) treatment are lacking in patients with structural heart disease undergoing concomitant CryoMaze procedures. The aim was to assess whether the timely pre-emptive catheter ablation would achieve higher freedom from AF or atrial tachycardia (AT) and be associated with better clinical outcomes than surgical ablation alone. METHODS AND

resultsThe trial investigated patients with non-paroxysmal AF undergoing coronary artery bypass grafting and/or valve repair/replacement with mandatory concomitant CryoMaze procedure who were randomly assigned to undergo either radiofrequency catheter ablation [Hybrid Group (HG)] or no further treatment (Surgery Group). The primary efficacy endpoint was the first recurrence of AF/AT without class I or III antiarrhythmic drugs as assessed by implantable cardiac monitors. The primary clinical endpoint was a composite of hospitalization for arrhythmia recurrence, worsening of heart failure, cardioembolic event, or major bleeding. We analysed 113 and 116 patients in the Hybrid and Surgery Groups, respectively, with a median follow-up of 715 (IQR: 528-1072) days. The primary efficacy endpoint was significantly reduced in the HG [41.1% vs. 67.4%, hazard ratio (HR) = 0.38, 95% confidence interval (CI): 0.26-0.57, P < 0.001] as well as the primary clinical endpoint (19.9% vs. 40.1%, HR = 0.51, 95% CI: 0.29-0.86, P = 0.012). The trial groups did not differ in all-cause mortality (10.6% vs. 8.6%, HR = 1.17, 95%CI: 0.51-2.71, P = 0.71). The major complications of catheter ablation were infrequent (1.9%).

conclusionPre-emptively performed catheter ablation after the CryoMaze procedure was safe and associated with higher freedom from AF/AT and improved clinical outcomes.

Indexed as

Atrial FibrillationCatheter AblationTachycardia, SupraventricularAnti-Arrhythmia AgentsHemorrhageHumansRecurrenceTreatment OutcomeAnti-Arrhythmia AgentsAtrial fibrillationCatheter ablationConcomitant atrial fibrillation ablationHybrid ablationMaze procedure

Identifiers

PMID38306687
PMCPMC10872694
OpenAlexW4391464708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.